Skip to content

ONO-3849 Phase II Study

A Multicenter open-labeled uncontrolled study in patients with Opioid-Induced Constipation

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221726
Enrollment
60
Registered
2012-02-29
Start date
2012-02-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-induced constipation

Interventions

investigational material(s) Generic name etc : ONO-3849 INN of investigational material : methylnaltrexone bromide Therapeutic category code : 235 Purgatives and clysters Dosage and Administration for

Sponsors

ONO PHARMACEUTICAL CO.,LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Age 20 years or older. 2.Patient with constipation on a stable opioid regimen.

Exclusion criteria

Exclusion criteria: 1.Patients with known or suspected gastrointestinal obstruction. 2.Patients with constipation mainly caused by any bowel dysfunction other than opioid-induced one.

Design outcomes

Primary

MeasureTime frame
Laxation response rate within 4 hours of study drug treatment without rescue laxatives.

Secondary

MeasureTime frame
Laxation response rate within 24 hours of study drug treatment without rescue laxatives, and so on.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026